Senescing oral dysplasias are not immortalized by ectopic expression of htert alone without other molecular changes, such as loss of ink4a and/or retinoic acid receptor-β: but p53 mutations are not necessarily required

ABSTRACT Our previous work showed that acquisition of immortality at the dysplasia stage of oral cancer progression was consistently associated with four changes: loss of retinoic acid

receptor (RAR)-_β_ and p16INK4A expression, p53 mutations and activation of telomerase. One atypical dysplasia (D17) that underwent delayed senescence after an extended lifespan showed loss

of RAR-_β_ and p16INK4A/p14ARF expression, but retained functional wild-type p53 and telomerase was not activated. We now demonstrate that retroviral delivery of hTERT results in telomere

lengthening and immortalization of D17 without loss of functional wild-type p53 activity. In contrast, the expression of hTERT in two other typical mortal dyplasia cultures (that retain

RAR-_β_ and p16INK4A expression) does not extend their lifespan, even though telomeres are lengthened. Access through your institution Buy or subscribe This is a preview of subscription

content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 50 print issues and online access $259.00 per year only $5.18 per issue

Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL

ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS REPROGRAMMING OF THE ESOPHAGEAL SQUAMOUS

CARCINOMA EPIGENOME BY SOX2 PROMOTES ADAR1 DEPENDENCE Article 10 May 2021 CHRONIC EXPRESSION OF P16INK4A IN THE EPIDERMIS INDUCES WNT-MEDIATED HYPERPLASIA AND PROMOTES TUMOR INITIATION

Article Open access 01 June 2020 A NON-GENETIC SWITCH TRIGGERS ALTERNATIVE TELOMERE LENGTHENING AND CELLULAR IMMORTALIZATION IN ATRX DEFICIENT CELLS Article Open access 20 February 2023

REFERENCES * Campisi J . (2000). _In vivo_, 14, 183–188. * Ghose A, Fleming J, El-Bayoumy K and Harrison PR . (2001). _Cancer Res._, 61, 7479–7487. * Gordon KE, Ireland H, Roberts M, Steegs

K, McCaul JA, MacDonald DG and Parkinson KE . (2002). _Cancer Res._, 63, 458–467. * Kresty LA, Mallery SR, Knobloch TJ, Song H, Lloyd M, Casto BC and Weghorst CM . (2002). _Cancer Res._, 62,

5295–5300. * Lustig AJ . (1999). _Proc. Natl. Acad. Sci. USA_, 96, 3339–3341. * McGregor F, Muntoni A, Fleming J, Brown J, Felix DH, MacDonald G, Parkinson EK and Harrison PR . (2002).

_Cancer Res._, 62, 4757–4766. * McGregor F, Wagner E, Felix D, Soutar D, Parkinson K and Harrison PR . (1997). _Cancer Res._, 57, 3886–3889. * Morris M, Hepburn P and Wynford-Thomas D .

(2002). _Oncogene_, 21, 4277–4288. * Munro J, Steeghs K, Morrison V, Ireland H and Parkinson EK . (2001). _Oncogene_, 20, 3541–3552. * Munro J, Stott FJ, Vousden KH, Peters G and Parkinson

EK . (1999). _Cancer Res._, 59, 2516–2521. * Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G and Hara E . (2001). _Nature_, 409, 1067–1070. * Pandita

TK . (2002). _Oncogene_, 21, 611–618. * Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelman WN, Lotan R, Hong WK and Mao L . (1997). _Oncogene_, 14,

1799–1803. * Ramirez RD, Morales CP, Herbert BS, Rohde JM, Passons C, Shay JW and Wright WE . (2001). _Genes Dev._, 15, 398–403. * Rheinwald JG and Beckett MA . (1981). _Cancer Res._, 41,

1657–1663. * Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catricala C and O'Toole KM . (2002). _Mol. Cell. Biol._, 22, 5157–5172. * Serrano M, Lin AW, McCurrach

ME, Beach D and Lowe SW . (1997). _Cell_, 88, 593–602. * Shay JW . (1997). _J. Cell. Physiol._, 173, 266–270. * Smogorzewska A and de Lange T . (2002). _EMBO J._, 21, 4338–4348. * Stewart SA

and Weinberg RA . (2002). _Oncogene_, 21, 627–630. * Vaziri H and Benchimol S . (1998). _Curr. Biol._, 8, 279–282. * Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T and

Wynford-Thomas D . (2000). _Mol. Cell. Biol._, 20, 2803–2808. * Xu D, Wang Q, Gruber A, Bjorkholm M, Chen Z, Zaid A, Selivanova G, Peterson C, Wiman KG and Pisa P . (2000). _Oncogene_, 19,

5123–5133. * Xu XC, Ro JY, Lee JS, Shin DM, Hong WK and Lotan R . (1994). _Cancer Res._, 54, 3580–3587. Download references ACKNOWLEDGEMENTS We are grateful to Dr H Vaziri for his generous

gift of the hTERT retroviral construct. We are grateful to Professors J Wyke and B Ozanne for critically reading the manuscript. AM was supported by the Glasgow Cancer School and White Lily

Trust; PRH, KEP, JF and KG by Cancer Research UK and KH by Glasgow University. AUTHOR INFORMATION Author notes * Alessandra Muntoni Present address: Children's Medical Research

Institute, 214 Hawkesbury Road, 2145, Westmead, NSW, Australia AUTHORS AND AFFILIATIONS * The Beatson Institute for Cancer Research, CRC Beatson Laboratories, Garscube Estate, Switchback

Road, Bearsden, Glasgow, G61 1BD, UK Alessandra Muntoni, Janis Fleming, Katrina E Gordon, Keith Hunter, Fiona McGregor, E Kenneth Parkinson & Paul R Harrison Authors * Alessandra Muntoni

View author publications You can also search for this author inPubMed Google Scholar * Janis Fleming View author publications You can also search for this author inPubMed Google Scholar *

Katrina E Gordon View author publications You can also search for this author inPubMed Google Scholar * Keith Hunter View author publications You can also search for this author inPubMed 

Google Scholar * Fiona McGregor View author publications You can also search for this author inPubMed Google Scholar * E Kenneth Parkinson View author publications You can also search for

this author inPubMed Google Scholar * Paul R Harrison View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Paul R

Harrison. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Muntoni, A., Fleming, J., Gordon, K. _et al._ Senescing oral dysplasias are not immortalized by

ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-_β_: but p53 mutations are not necessarily required. _Oncogene_ 22,

7804–7808 (2003). https://doi.org/10.1038/sj.onc.1207085 Download citation * Received: 07 January 2003 * Revised: 16 July 2003 * Accepted: 05 August 2003 * Published: 30 October 2003 * Issue

Date: 30 October 2003 * DOI: https://doi.org/10.1038/sj.onc.1207085 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry,

a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * head and neck cancer *

preneoplasia * immortalization * RAR-_β_ * INK4A * telomerase